Analysts Set Uniqure NV (QURE) Target Price at $20.29
Shares of Uniqure NV (NASDAQ:QURE) have been assigned a consensus recommendation of “Buy” from the eleven analysts that are presently covering the firm, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $20.29.
QURE has been the topic of several recent research reports. Zacks Investment Research lowered Uniqure from a “hold” rating to a “sell” rating in a report on Wednesday, October 18th. Leerink Swann increased their price target on Uniqure from $17.00 to $19.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Evercore ISI initiated coverage on Uniqure in a report on Tuesday, November 7th. They set an “outperform” rating and a $22.00 price target on the stock. Oppenheimer restated a “hold” rating on shares of Uniqure in a report on Friday, November 24th. Finally, HC Wainwright initiated coverage on Uniqure in a report on Friday, December 1st. They set a “buy” rating and a $28.00 price target on the stock.
Uniqure (QURE) traded up $3.15 during trading hours on Friday, reaching $22.32. The company had a trading volume of 635,900 shares, compared to its average volume of 413,432. Uniqure has a one year low of $4.72 and a one year high of $22.45. The stock has a market cap of $590.44, a price-to-earnings ratio of -8.55 and a beta of 0.57. The company has a quick ratio of 3.64, a current ratio of 3.64 and a debt-to-equity ratio of 0.73.
Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in shares of Uniqure during the fourth quarter valued at $119,000. Virtus Fund Advisers LLC purchased a new position in shares of Uniqure during the fourth quarter valued at $389,000. OxFORD Asset Management LLP purchased a new position in shares of Uniqure during the third quarter valued at $399,000. JPMorgan Chase & Co. increased its stake in shares of Uniqure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares during the period. Finally, Victory Capital Management Inc. purchased a new position in shares of Uniqure during the fourth quarter valued at $1,298,000. Hedge funds and other institutional investors own 25.10% of the company’s stock.
WARNING: This story was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://theolympiareport.com/2018/02/13/analysts-set-uniqure-nv-qure-target-price-at-20-29.html.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.